Incannex Commences Participant Screening in DReAMzz Phase 2 Study of IHL-42X for Obstructive Sleep Apnea

Phase 2IHL-42XPositive

AI Analysis

Summary

Incannex Healthcare has commenced participant screening for the DReAMzz Phase 2 dose confirmation study of IHL-42X for obstructive sleep apnea treatment. The candidate has previously received FDA Fast Track designation, supporting potential expedited development.

Clinical Trial Data

Phase

Phase 2

Outcome Details

Participant screening commenced in DReAMzz Phase 2 dose confirmation study

Importance:5/10

Sentiment:

0.60

Phase 2Clinical TrialOSAFast Track DesignationTrial Initiation

Related Companies

$IXHL

Read the original article

Published by GlobeNewswire Clinical Studies on July 23, 2026 12:00 PM

Read Original